Latest Approaches to Treating Lymphoma and Myeloma With CAR T-Cell Therapy – Strategies for Integrating Into Practice
Release Date: November 15, 2019
Expiration Date: November 15, 2020
Estimated time to complete activity: .5 hour
This activity is jointly provided by The Postgraduate Institute for Medicine and Bio Ascend.
Expert Insights is an accredited videotaped discussion featuring Dr Julie Vose and Dr Bianca Santomasso highlighting the most clinically relevant data presented from the September 13th CAR T symposium from the 2019 Society of Hematologic Oncology Annual Meeting in Houston, Texas.
This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.
After completing this activity, the participant should be better able to:
- Explain the mechanism of action of CAR T-cell-based therapy and the rationale for their investigation and use in patients with lymphoma and multiple myeloma (MM)
- Evaluate clinical data of current and emerging CAR T-cell therapies for patients with lymphoma
- Assess clinical trial results from CAR T cells being investigated in patients with MM
- Anticipate adverse events that may occur with CAR T-cell therapy, and develop strategies to mitigate these AEs
Julie M. Vose, MD, MBA - Chair
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Grants/Research Support, Consultant: AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited
Bianca Santomasso, MD, PhD
Neuro-oncologist & Neurologist
Memorial Sloan Kettering Cancer Center
New York, New York
Consulting Fees: Kite/Gilead
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Bio Ascend planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There is no fee for this educational activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Materials will be available online through November 15, 2020.
This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.